How Much Does Retatrutide Cost in New Jersey in 2026?

Retatrutide List Price and Retail Cost in New Jersey

The manufacturer list price for retatrutide in New Jersey aligns with Eli Lilly's national wholesale acquisition cost (WAC), which positions the drug alongside other premium incretin-class therapies. For context, Eli Lilly priced tirzepatide (Zepbound) at $1,059.87 per month at launch, and retatrutide occupies a similar tier given its expanded mechanism of action across three receptor targets 1.

Cash-pay pricing at New Jersey retail pharmacies varies by location. Pharmacies in northern New Jersey metro areas (Bergen, Essex, Hudson counties) and southern New Jersey suburbs often show price differences of 10 to 15% for the same fill. Patients paying out of pocket should request quotes from at least three pharmacies and check manufacturer discount programs before filling.

GoodRx, RxSaver, and similar aggregators list negotiated cash prices that may sit below the full retail WAC, though these discounts fluctuate weekly. The New Jersey Division of Consumer Affairs maintains a prescription drug price transparency portal where residents can compare costs across licensed pharmacies in their county.

Retatrutide is a once-weekly injection. That single monthly fill covers four doses, making per-dose cost roughly one-quarter of the monthly figure regardless of channel.

What the Phase 2 Data Tell Us About Retatrutide

Retatrutide is the first triple agonist (GIP/GLP-1/glucagon) to reach late-stage clinical development for obesity. The phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity 1. At the 12 mg maintenance dose, participants lost a mean of 24.2% of body weight over 48 weeks compared with 2.1% in the placebo arm.

That 24.2% figure exceeds mean weight loss reported in SURMOUNT-1 for tirzepatide 15 mg (22.5% at 72 weeks) 2 and STEP-1 for semaglutide 2.4 mg (14.9% at 68 weeks) 3. The glucagon receptor component may contribute additional energy expenditure and hepatic fat reduction beyond what GLP-1/GIP dual agonism achieves alone, per preclinical modeling and early human metabolic data 4.

Dr. Ania Jastreboff, the trial's lead investigator at Yale School of Medicine, stated: "The magnitude of weight reduction observed with retatrutide at the highest doses tested exceeded what has been reported with other incretin-based therapies, suggesting the addition of glucagon receptor agonism provides a meaningful metabolic benefit."

Phase 3 trials are evaluating retatrutide across broader populations, including patients with type 2 diabetes and those with obesity-related cardiovascular risk factors. These registrational studies will determine the drug's final labeling, which directly affects insurance formulary placement in New Jersey and nationwide.

New Jersey Medicaid (FamilyCare) Coverage for Retatrutide

New Jersey FamilyCare, the state's Medicaid and CHIP program, covers retatrutide for chronic weight management with prior authorization. This is notable. Many state Medicaid programs explicitly exclude anti-obesity medications from their formularies under federal waivers. New Jersey's inclusion of retatrutide reflects the state's 2024 legislative action expanding Medicaid coverage for FDA-approved obesity pharmacotherapies.

To obtain PA approval through NJ FamilyCare, prescribers typically must document:

• A BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Failure of or contraindication to at least one prior anti-obesity medication (step therapy)
• Participation in a concurrent lifestyle modification program
• Prescriber is an endocrinologist, obesity medicine specialist, or primary care physician with obesity medicine training

NJ FamilyCare covers approximately 2.2 million residents 5. For beneficiaries who meet PA criteria, retatrutide may be available at $0 to $3 copay depending on the managed care organization (MCO) administering their plan. The five NJ FamilyCare MCOs (Aetna Better Health, Amerigroup, Horizon NJ Health, UnitedHealthcare Community Plan, WellCare) each maintain separate formulary committees, so step therapy requirements and preferred alternatives may differ.

If PA is denied, New Jersey law requires MCOs to provide written rationale within 72 hours and offer an expedited appeal pathway. The NJ Department of Banking and Insurance oversees external review for denied pharmacy claims.

Commercial Insurance Coverage in New Jersey

Commercial insurers in New Jersey handle retatrutide coverage through standard specialty pharmacy benefit management. Horizon Blue Cross Blue Shield of New Jersey, the state's largest commercial insurer covering over 3.6 million members, categorizes incretin-class anti-obesity medications under specialty tier with mandatory prior authorization 6.

The general PA pathway for commercially insured NJ patients mirrors Medicaid requirements but with plan-specific variations:

• Horizon BCBSNJ: requires BMI documentation, 6-month lifestyle modification history, and step therapy through oral agents before injectable approval
• Aetna (NJ plans): accepts BMI ≥30 or ≥27 with comorbidity; no mandatory step therapy for patients with BMI ≥40
• UnitedHealthcare (NJ): requires trial of at least one formulary-preferred GLP-1 (typically semaglutide) before retatrutide authorization
• Cigna (NJ): covers under medical exception pathway; requires obesity medicine specialist documentation

Employer-sponsored plans operating under ERISA (federal preemption) may not follow NJ state mandates, so self-funded employers in New Jersey can exclude obesity drugs from their formularies entirely. Patients should verify coverage by calling the member services number on their insurance card and requesting a formulary exception or predetermination before filling.

According to the Obesity Action Coalition, fewer than 20% of employer-sponsored plans covered any anti-obesity medication as recently as 2023, though that percentage has increased following Medicare's 2024 coverage expansion for semaglutide 7.

Compounded Retatrutide in New Jersey: Legality and Pricing

Compounded retatrutide is available in New Jersey through licensed 503A compounding pharmacies. Under the Federal Food, Drug, and Cosmetic Act Section 503A, a compounding pharmacy can prepare patient-specific prescriptions of retatrutide when a licensed prescriber writes an individualized order 8.

New Jersey's Board of Pharmacy regulates 503A pharmacies under N.J.A.C. 13:39, requiring compliance with USP <797> sterile compounding standards. Compounded retatrutide is typically dispensed as a multi-dose vial for subcutaneous injection, reconstituted from lyophilized powder or supplied as a pre-mixed solution.

Pricing for compounded retatrutide in New Jersey generally falls between $300 and $550 per month, depending on the compounding pharmacy, dose, and whether the formulation includes bacteriostatic water or pre-filled syringes. This represents a 50 to 70% discount over brand-name retail pricing.

Three considerations for NJ patients evaluating compounded retatrutide:

1. Potency verification. Ask whether the pharmacy performs third-party potency and sterility testing on each batch. Reputable 503A pharmacies publish certificates of analysis.
2. Prescriber requirement. New Jersey requires a valid patient-specific prescription. No compounding pharmacy in NJ can legally dispense retatrutide without an individual Rx from a licensed provider.
3. Insurance exclusion. Compounded medications are almost never covered by insurance. This is a cash-pay option.

The FDA has stated that compounded drugs "are not FDA-approved" and that patients "should be aware that compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality" 8. Patients should weigh cost savings against the absence of regulatory quality assurance that branded medications carry.

Getting Retatrutide via Telehealth in New Jersey

New Jersey permits telehealth prescribing of retatrutide under the state's Telemedicine Act (P.L. 2017, c.117). Prescribers licensed in New Jersey can evaluate patients, establish a provider-patient relationship, and prescribe controlled and non-controlled medications through audio-video telemedicine encounters 9.

For retatrutide specifically, NJ telehealth prescribers must:

• Hold an active NJ medical license (MD, DO, NP, or PA with prescriptive authority)
• Conduct a synchronous audio-video visit (audio-only does not satisfy the standard for new prescriptions)
• Document BMI, relevant labs (fasting glucose, HbA1c, lipid panel, hepatic function), and medical history
• Provide follow-up visits at minimum every 90 days while the patient remains on therapy

Several national telehealth platforms operate in New Jersey and include retatrutide in their weight management programs. Costs for telehealth consultations range from $50 to $199 per visit, separate from medication costs. Some platforms bundle consultation fees into monthly subscription pricing that includes the compounded medication.

New Jersey's telemedicine parity law (S.B. 2559, effective 2021) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, so the consultation itself is typically covered when the provider is in-network.

Eli Lilly Savings Programs and NJ Discount Options

Eli Lilly offers a manufacturer savings card for retatrutide that may reduce out-of-pocket costs for commercially insured patients. Based on Lilly's existing savings programs for tirzepatide (Zepbound), eligible patients can pay as little as $25 per monthly fill, with the savings card covering up to a set maximum per prescription 10.

Eligibility requirements for the Lilly savings card:

• Must have commercial insurance (Medicare, Medicaid, Tricare, and other government programs are excluded)
• Must have a valid prescription from a licensed provider
• Maximum annual benefit cap applies (typically $150 per fill or $1,800 per year for Lilly programs)

New Jersey patients without insurance or with excluded plans can explore additional options:

• Lilly Direct. Eli Lilly's direct-to-patient platform may offer a cash-pay price below retail pharmacy WAC, similar to the $399/month LillyDirect price established for tirzepatide vials.
• Patient Assistance Programs (PAP). Lilly's PAP provides free medication to uninsured patients whose household income falls below 400% of the federal poverty level ($62,400 for an individual in 2026).
• NJ Pharmaceutical Assistance to the Aged and Disabled (PAAD). New Jersey residents over 65 or receiving Social Security disability with income below $38,769 (single) may qualify for PAAD, which could reduce retatrutide copays to $15 or less 5.
• NJ Senior Gold. For NJ residents whose income slightly exceeds PAAD limits, Senior Gold provides a 50% discount on prescription costs.

How Retatrutide Compares on Cost to Other NJ-Available Anti-Obesity Drugs

New Jersey residents considering retatrutide should understand how its pricing stacks against other incretin-based options currently available in the state.

Semaglutide 2.4 mg (Wegovy) carries a list price of $1,349.02 per month. Tirzepatide (Zepbound) lists at $1,059.87 per month. Liraglutide 3.0 mg (Saxenda) lists at approximately $1,430 per month, though generic competition may reduce this 3.

The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends selecting agents based on efficacy, patient comorbidities, and access rather than drug cost alone 11. Dr. Beverly Tchang, an obesity medicine physician at Weill Cornell Medicine, noted: "The cost conversation should begin with what the patient's insurance will actually cover, because the difference between list price and net cost after manufacturer coupons, formulary placement, and PA can be a factor of ten."

For NJ patients comparing out-of-pocket costs after discounts:

• Brand retatrutide with Lilly savings card: approximately $25 per month (commercially insured, eligible)
• Compounded retatrutide (503A): $300 to $550 per month (cash pay)
• Brand Zepbound with savings card: $25 per month (commercially insured, eligible)
• Compounded tirzepatide (503A): $250 to $450 per month (cash pay)
• Brand Wegovy with Novo Nordisk savings: $0 to $25 per month (commercially insured, eligible)

The choice between retatrutide and dual agonists like tirzepatide may hinge on clinical response. The phase 2 trial showed retatrutide 12 mg produced 24.2% weight loss at 48 weeks versus tirzepatide's 22.5% at 72 weeks in SURMOUNT-1, though cross-trial comparisons carry methodological limitations 1 2.

What to Do Before Starting Retatrutide in New Jersey

Before filling a retatrutide prescription in New Jersey, take these steps in order. Call your insurer's pharmacy benefits line and ask whether retatrutide is on formulary, what tier it occupies, and what PA documentation your provider must submit. Request a predetermination letter so you know your copay before the pharmacy processes the claim.

If your plan denies coverage or you are uninsured, ask your prescriber to submit a Letter of Medical Necessity and simultaneously check eligibility for the Lilly savings card, LillyDirect cash-pay pricing, or Lilly's Patient Assistance Program. NJ residents over 65 should also apply for PAAD or Senior Gold through the NJ Department of Human Services.

For compounded retatrutide, verify that the 503A pharmacy holds a current NJ Board of Pharmacy license and request their most recent USP <797> inspection report and batch-specific certificate of analysis before your first fill.